Purpose To evaluate the dosimetric characteristics and applications of a dosimetry system composed of a flexible amorphous silicon thin‐film solar cell and scintillator screen (STFSC‐SS) for therapeutic X‐rays. Methods The real‐time dosimetry system was composed of a flexible a‐Si thin‐film solar cell (0.2‐mm thick), a scintillator screen to increase its efficiency, and an electrometer to measure the generated charge. The dosimetric characteristics of the developed system were evaluated including its energy dependence, dose linearity, and angular dependence. Calibration factors for the signal measured by the system and absorbed dose‐to‐water were obtained by setting reference conditions. The application and correction accuracy of the developed system were evaluated by comparing the absorbed dose‐to‐water measured using a patient treatment beam with that measured using the ion chamber. Results The responses of STFSC‐SS to energy, field size, depth, and source‐to‐surface distance (SSD) were more dependent on measurement conditions than were the responses of the ion chamber, although the former dependence was due to the scintillator screen, not the solar cell. The signals of STFSC‐SS were also dependent on dose rate, while the responses of solar cell alone and scintillator screen were not dependent on dose rate. The scintillator screen reduced the output of solar cell at 6 and 15 MV by 0.60 and 0.55%, respectively. The different absorbed dose‐to‐water measured using STFSC‐SS for patient treatment beam differed by 0.4% compared to those measured using the ionization chamber. The uncertainties of the developed system for 6 and 15 MV photon beams were 1.8 and 1.7%, respectively, confirming the accuracy and applicability of this system. Conclusions The thin‐film solar cell‐based detector developed in this study can accurately measure absorbed dose‐to‐water. The increased signal resulting from the use of the scintillator screen is advantageous for measuring low doses and stable signal output. In addition, this system is flexible, making it applicable to curved surfaces, such as a patient's body, and is cost‐effective.

PurposeTo evaluate the quality of patient‐specific complicated treatment plans, including commercialized treatment planning systems (TPS) and commissioned beam data, we developed a process of quality assurance (QA) using a Monte Carlo (MC) platform. Specifically, we constructed an interface system that automatically converts treatment plan and dose matrix data in digital imaging and communications in medicine to an MC dose‐calculation engine. The clinical feasibility of the system was evaluated.Materials and MethodsA dose‐calculation engine based on GATE v8.1 was embedded in our QA system and in a parallel computing system to significantly reduce the computation time. The QA system automatically converts parameters in volumetric‐modulated arc therapy (VMAT) plans to files for dose calculation using GATE. The system then calculates dose maps. Energies of 6 MV, 10 MV, 6 MV flattening filter free (FFF), and 10 MV FFF from a TrueBeam with HD120 were modeled and commissioned. To evaluate the beam models, percentage depth dose (PDD) values, MC calculation profiles, and measured beam data were compared at various depths (Dmax, 5 cm, 10 cm, and 20 cm), field sizes, and energies. To evaluate the feasibility of the QA system for clinical use, doses measured for clinical VMAT plans using films were compared to dose maps calculated using our MC‐based QA system.ResultsA LINAC QA system was analyzed by PDD and profile according to the secondary collimator and multileaf collimator (MLC). Values for MC calculations and TPS beam data obtained using CC13 ion chamber (IBA Dosimetry, Germany) were consistent within 1.0%. Clinical validation using a gamma index was performed for VMAT treatment plans using a solid water phantom and arbitrary patient data. The gamma evaluation results (with criteria of 3%/3 mm) were 98.1%, 99.1%, 99.2%, and 97.1% for energies of 6 MV, 10 MV, 6 MV FFF, and 10 MV FFF, respectively.ConclusionsWe constructed an MC‐based QA system for evaluating patient treatment plans and evaluated its feasibility in clinical practice. We observed robust agreement between dose calculations from our QA system and measurements for VMAT plans. Our QA system could be useful in other clinical settings, such as small‐field SRS procedures or analyses of secondary cancer risk, for which dose calculations using TPS are difficult to verify.

In these days, 3D-printer is on the rise in various fields including radiation therapy. This preliminary study aimed to estimate the dose characteristics of the 3D-printer materials which could be used as the compensator or immobilizer in radiation treatment. The cubes which have 5cm length and different densities as 50%, 75% and 100% were printed by 3D-printer.A planning CT scans for cubes were performed using a CT simulator (Brilliance CT, Philips Medical System, Netherlands). Dose distributions behind the cube were calculated when 6MV photon beam passed through cube. The dose response for 3D-printed cube, air and water were measured by using EBT3 film and 2D array detector. When results of air case were normalized to 100, dose calculated by TPS and measured dose of 50% and 75% cube were 96~99. Measured and calculated doses of water and 100% cube were 82~84. HU values of 50%, 75% and 100% were -910, -860 and -10, respectively. From these results, 3D-printer in radiotherapy could be used for medical purpose accurately.

Background The purpose of this study is to develop a clinical application program that automatically calculates the effect for secondary cancer risk (SCR) of individual patient. The program was designed based on accurate dose calculations using patient computed tomography (CT) data and Monte Carlo engine. Automated patient-specific evaluation program was configured to calculate SCR. Methods The application program is designed to re-calculate the beam sequence of treatment plan using the Monte Carlo engine and patient CT data, so it is possible to accurately calculate and evaluate scatter and leakage radiation, difficult to calculate in TPS. The Monte Carlo dose calculation system was performed through stoichiometric calibration using patient CT data. The automatic SCR evaluation program in application program created with a MATLAB was set to analyze the results to calculate SCR. The SCR for organ of patient was calculated based on Biological Effects of Ionizing Radiation (BEIR) VII models. The program is designed to sequentially calculate organ equivalent dose (OED), excess absolute risk (EAR), excess relative risk (ERR), and the lifetime attributable risk (LAR) in consideration of 3D dose distribution analysis. In order to confirm the usefulness of the developed clinical application program, the result values from clinical application program were compared with the manual calculation method used in the previous study. Results The OED values calculated in program were calculated to be at most approximately 13.3% higher than results in TPS. The SCR result calculated by the developed clinical application program showed a maximum difference of 1.24% compared to the result of the conventional manual calculation method. And it was confirmed that EAR, ERR and LAR values can be easily calculated by changing the biological parameters. Conclusions We have developed a patient-specific SCR evaluation program that can be used conveniently in the clinic. The program consists of a Monte Carlo dose calculation system for accurate calculation of scatter and leakage radiation and a patient-specific automatic SCR evaluation program using 3D dose distribution. The clinical application program that improved the disadvantages of the existing process can be used as an index for evaluating a patient treatment plan.

No abstract